We have located links that may give you full text access.
Journal Article
Review
Off-label use of biologicals in the management of inflammatory oral mucosal disease.
Journal of Oral Pathology & Medicine 2008 November
The recent development of novel biologic immunomodulators effective in the treatment of immune-mediated inflammatory conditions has led to their widespread use in rheumatology and dermatology. These include the tumour necrosis factor-alpha antagonists, infliximab, etanercept and adalimumab and the T-cell modulator modifiers efalizumab and alefacept. In dermatology, although these agents are licensed only for psoriasis, increasingly off-label use has extended to a number of conditions in which oral mucosal disease is a significant component. These include Behçet's disease, recurrent apthous stomatitis, benign mucous membrane pemphigoid and lichen planus. This article provides a review of the current literature on such off-label use in oral mucosal disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app